CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 83 enrolled
Drug / intervention
exenatide +3 moredrug
Likely dose
exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00729326
NCT00729326Phase 4Completed
CompareCT.gov

Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

AstraZeneca·interventional·Posted Aug 7, 2008·Updated Apr 9, 2015

In Brief

A Phase 4 clinical trial evaluating exenatide, sitagliptin, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 83 participants across 1 site.

Detailed Summary

This study is designed to compare the short-term effects and mechanisms of action of exenatide with those of sitagliptin when either is added to an oral agent(metformin or a thiazolidinedione \[TZD\]) in adult patients with type 2 diabetes mellitus(T2DM) with inadequate glycemic control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2008
Enrollment StartAug 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.9 years ago

Interventions

exenatidedrug

subcutaneous injection (5mcg or 10mcg), twice a day

sitagliptindrug

oral administration (100mg), once a day in the morning

placebodrug

subcutaneous injection (5mcg or 10mcg), twice a day

placebodrug

oral administration (100mg), once a day in the morning